C5 and Guillain-Barre syndrome: Inhibition of C5 complement component activation in experimental ex vivo and in vivo GBS models was extensively used to investigate the pathogenesis of GBS and to evaluate complement deposition in the nerve membrane [55,56,57,58,59].